Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative, open trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Youn I. | - |
dc.contributor.author | Chung, Jun Won | - |
dc.contributor.author | Park, Dong Kyun | - |
dc.contributor.author | Kim, Kyoung Oh | - |
dc.contributor.author | Kwon, Kwang An | - |
dc.contributor.author | Kim, Yoon Jae | - |
dc.contributor.author | Seo, Ja Young | - |
dc.date.available | 2020-04-06T07:39:33Z | - |
dc.date.created | 2020-04-02 | - |
dc.date.issued | 2019-12-14 | - |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/26467 | - |
dc.description.abstract | BACKGROUND Few studies have compared the efficacy and safety profile of a tailored eradication (TR) strategy based on the presence of a 23S ribosomal RNA point mutation with those of empirical bismuth-based quadruple therapy (EBQT) for first-line eradication of Helicobacter pylori (H. pylori) in Korean patients. AIM To compare the efficacy and safety of a TR strategy and those of EBQT regimen as first-line eradication therapy for H. pylori. METHODS This is an open-label, comparative study in which we prospectively enrolled patients over 18 years of age with H. pylori infection and retrospectively reviewed their data. H. pylori-positive patients diagnosed by rapid urease test, Giemsa staining, or dual priming oligonucleotide polymerase chain reaction (DPO-PCR) were enrolled from May 2016 to September 2018 at Gil Medical Center. Patients with H. pylori infection received either a TR regimen or the EBQT regimen. In the tailored therapy group that underwent DPO-PCR testing, patients with A2142G and/or A2143G point mutations were treated with a bismuth-containing quadruple regimen. The eradication rate, patient-reported side effect rate, and H. pylori eradication success rate were evaluated and compared between the groups. RESULTS A total of 150 patients were assigned to the TR (n = 50) or EBQT group (n = 100). The first-line eradication rate of H. pylori did not differ between the groups (96.0% vs 95.7%, P = 0.9). The rate of eradication-related side effects for TR was 12.0%, which differed significantly from that of EBQT (43.0%) for first-line treatment (P < 0.001). CONCLUSION DPO-PCR-based TR for H. pylori eradication may be equally efficacious, with less treatment-related complications, compared to EBQT in Korea, where clarithromycin resistance is high. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BAISHIDENG PUBLISHING GROUP INC | - |
dc.relation.isPartOf | WORLD JOURNAL OF GASTROENTEROLOGY | - |
dc.subject | TRIPLE THERAPY | - |
dc.subject | SUSCEPTIBILITY | - |
dc.subject | ASSOCIATION | - |
dc.subject | INFECTION | - |
dc.title | Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative, open trial | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000511324500004 | - |
dc.identifier.doi | 10.3748/wjg.v25.i46.6743 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF GASTROENTEROLOGY, v.25, no.46, pp.6743 - 6751 | - |
dc.identifier.scopusid | 2-s2.0-85077165406 | - |
dc.citation.endPage | 6751 | - |
dc.citation.startPage | 6743 | - |
dc.citation.title | WORLD JOURNAL OF GASTROENTEROLOGY | - |
dc.citation.volume | 25 | - |
dc.citation.number | 46 | - |
dc.contributor.affiliatedAuthor | Choi, Youn I. | - |
dc.contributor.affiliatedAuthor | Chung, Jun Won | - |
dc.contributor.affiliatedAuthor | Park, Dong Kyun | - |
dc.contributor.affiliatedAuthor | Kim, Kyoung Oh | - |
dc.contributor.affiliatedAuthor | Kwon, Kwang An | - |
dc.contributor.affiliatedAuthor | Kim, Yoon Jae | - |
dc.contributor.affiliatedAuthor | Seo, Ja Young | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Helicobacter pylori | - |
dc.subject.keywordAuthor | Eradication | - |
dc.subject.keywordAuthor | Tailored | - |
dc.subject.keywordAuthor | Empirical | - |
dc.subject.keywordAuthor | Quadruple | - |
dc.subject.keywordPlus | TRIPLE THERAPY | - |
dc.subject.keywordPlus | SUSCEPTIBILITY | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | INFECTION | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.